Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study

AIDS

Volumn 16, Issue 5, 2002, Pages

  Noor, Mustafa A ^a,b   Seneviratne, Tara ^a,b   Aweeka, Francesca T ^c   Lo, Joan C ^a,d   Schwarz, Jean Marc ^a,d,e   Mulligan, Kathleen ^a,d   Schambelan, Morris ^a,d   Grunfeld, Carl ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Diabetes; Glucose transport; HIV; HIV protease inhibitors; Indinavir; Insulin resistance; Lipodystrophy; Metabolic complications

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 4; INDINAVIR; INSULIN; LIPID; LIPOPROTEIN; PLACEBO; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GLUCOSE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; INSULIN; MALE; MIDDLE AGED;

EID: 0037192590     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00002     Document Type: Article

References (30)

1. Disorders of glucose metabolism in patients infected with human immunodeficiency virus
2. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
3. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
4. Insulin resistance in HIV protease inhibitor-associated diabetes
5. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and b-cell function in HIV-infected patients
6. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
7. Metabolic effects of indinavir in healthy HIV-seronegative men
8. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
9. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle
10. HIV-protease inhibitors
11. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
12. Glucose clamp technique: A method for quantifying insulin secretion and resistance
13. The theoretical bases of indirect calorimetry: A review
14. An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma
15. Indinavir concentrations and antiviral effect
16. Signaling mechanisms that regulate glucose transport
17. Molecular basis of insulin-stimulated GLUT-4 vesicle trafficking. Location! Location! Location!
18. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus
19. The insulin-sensitive glucose transporter
20. Single-dose pharmacokinetics of indinavir and the effect of food
21. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance
22. The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells
23. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes
24. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: Results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiencny virus
25. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy
26. Dietary regulation of glucose transporter gene expression: Tissue specific effects in adipose cells and muscle
27. Adipose-selective targeting of the GLUT-4 gene impairs insulin action in muscle and liver
28. Obesity and insulin resistance
29. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
30. Indinavir induces acute and reversible insulin resistance in rats